Synthetic Cleavage-Resistant TREM2: A Breakthrough for Macrophage Efferocytosis in Inflammatory Diseases

Study Background and Research Question

Efficient clearance of apoptotic cells by macrophages—known as efferocytosis—is a fundamental aspect of tissue homeostasis and resolution of inflammation. The triggering receptor expressed on myeloid cells 2 (TREM2) orchestrates this process by recognizing cell debris and activating downstream phagocytic signaling. However, during inflammation, upregulation of the sheddase ADAM17 leads to proteolytic cleavage of TREM2, disrupting its signaling and impairing macrophage function. This compromised efferocytosis results in the pathological accumulation of apoptotic cells and fuels chronic inflammation, observed in conditions ranging from metabolic-dysfunction-associated steatohepatitis (MASH) to atherosclerosis. Thus, the central research question addressed by Dong et al. was whether it is possible to engineer a TREM2 variant resistant to such proteolytic cleavage, and if so, whether this could restore macrophage efferocytosis and mitigate inflammatory disease.

Key Innovation from the Reference Study

The study's primary innovation lies in the rational design of a synthetic, cleavage-resistant TREM2 receptor (CRT). By integrating TREM2's ligand-binding domain with its intracellular adaptor DAP12 via a custom-engineered stalk and transmembrane segment, the authors created a receptor variant that resists ADAM17-mediated shedding. Unlike wild-type TREM2, CRT maintains surface expression and signaling capacity even in inflammatory contexts where ADAM17 activity is elevated. Functionally, CRT amplifies efferocytosis-related signaling and enhances the ability of macrophages to clear apoptotic cells.

Methods and Experimental Design Insights

To validate the function of CRT, Dong et al. combined molecular engineering, cell biology, and in vivo disease modeling:

• They constructed the CRT receptor by modifying the stalk and transmembrane domains to prevent proteolytic cleavage without disrupting ligand binding or DAP12 association.
• Murine macrophages were transfected with CRT or wild-type TREM2 via mRNA delivery, using phosphatidylserine-functionalized lipid nanoparticles (LNPs) for targeted uptake.
• The impact on efferocytosis was assessed in vitro by measuring phagocytosis of apoptotic cells and quantifying downstream signaling events.
• In vivo, mice were administered CRT-encoding LNP-mRNA to generate CRT-expressing macrophages (CRT-Ms) in situ.
• Therapeutic efficacy was tested in mouse models of MASH and atherosclerosis, evaluating tissue inflammation, apoptotic cell burden, and disease-associated pathology.

Protocol Parameters

• LNP-mRNA formulation: Phosphatidylserine-functionalized LNPs optimized for macrophage-targeted delivery.
• mRNA dose: Doses and injection schedules tuned to achieve effective in situ transfection in mouse models.
• Apoptotic cell clearance assays: Labeled target cells and quantitative imaging to assess efferocytic capacity.
• Inflammation and pathology readouts: Serum biomarkers, histopathology, and immunofluorescence to measure disease burden.

Core Findings and Why They Matter

The study demonstrated several key outcomes:

• CRT resists ADAM17-mediated shedding, maintaining membrane localization and functional signaling under inflammatory conditions.
• CRT-expressing macrophages (CRT-Ms) displayed enhanced efferocytosis compared to controls, both in vitro and in vivo.
• In mouse models of MASH and atherosclerosis, in situ generated CRT-Ms reduced apoptotic cell accumulation and attenuated tissue inflammation.
• Importantly, the CRT strategy restored TREM2-dependent pathways that are otherwise compromised during chronic inflammation, suggesting a generalizable approach to treating diseases characterized by defective apoptotic cell clearance.

These findings establish proof-of-principle that engineering protease-resistant immunoreceptors can overcome inflammation-induced signaling deficits in macrophages. This has broad implications for therapeutic strategies targeting efferocytosis in a range of pathological contexts.

Comparison with Existing Internal Articles

Several internal resources discuss the technical aspects of RNA probe preparation and in vitro transcription, which are foundational to the mRNA engineering and delivery components of the Dong et al. study. For example, the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit is highlighted for its customizable, high-yield synthesis of fluorescent RNA probes via T7 RNA polymerase-driven transcription. This is directly relevant to workflows requiring precise mRNA labeling and detection, such as optimizing mRNA constructs for LNP delivery and downstream tracking in cell-based assays.

Other internal articles, such as Reliable Fluorescent RNA Probe Synthesis with HyperScribe, provide scenario-driven insights into troubleshooting and optimizing probe synthesis for hybridization-based detection—techniques that, while not the central focus of Dong et al., underpin much of the experimental infrastructure for validating mRNA delivery and expression in cellular and tissue contexts. These resources collectively reinforce the importance of robust in vitro transcription and RNA labeling methods in contemporary molecular immunology and cell engineering research.

Limitations and Transferability

Despite its promising results, the CRT strategy has several limitations. First, while the engineering of the CRT receptor was effective in mouse models, further studies are needed to assess immunogenicity and long-term stability in human cells. Second, the use of LNP-mRNA systems for in situ cell engineering, while increasingly validated, requires precise control over dosing and delivery to avoid off-target effects. Finally, the generalizability of CRT-mediated efferocytosis enhancement to other inflammatory or degenerative diseases remains to be systematically explored.

Transferability to other disease models will depend on the extent to which impaired efferocytosis via TREM2 cleavage is a driving factor in the pathology. The current evidence supports strong applicability in settings like MASH and atherosclerosis, but broader use will need disease-specific validation.

Why this cross-domain matters, maturity, and limitations

The bridge between fundamental immunoreceptor engineering and therapeutic intervention in chronic inflammatory disease exemplifies translational immunology at its most impactful. The successful demonstration of mRNA-based in situ cell engineering, using LNPs for tissue-specific targeting, mirrors recent advances in mRNA vaccine technology and cell therapy. However, the maturity of this approach for clinical use is still early-stage: while preclinical results are robust, significant hurdles in regulatory approval, scalability, and safety must be addressed before human translation.

Research Support Resources

For researchers seeking to recreate or extend these workflows, high-quality RNA probe synthesis is essential—whether for validating mRNA delivery or for downstream hybridization-based detection (e.g., in situ hybridization probe preparation or Northern blot hybridization probe analysis). The HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit (SKU K1062) from APExBIO provides a robust, customizable platform for generating fluorescently labeled RNA probes using T7 RNA polymerase transcription and Cy5-UTP incorporation. This Cy5 RNA labeling kit is suitable for sensitive detection needs in molecular workflows analogous to those used in this study.